Clinical Trials & Research Studies

Dr. Knight and his team are involved in numerous clinical trials and research studies focused on understanding APS and lupus, and developing new, personalized treatment options. In addition, the team is also investigating COVID-19.

COVID-19 Clinical Trial

Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
The most severe manifestations of COVID-19 include respiratory failure, coagulation problems, and death. Inflammation and blood clotting are believed to play an important role in these manifestations. Research in humans has shown that dipyridamole can reduce blood clotting. This research study is being conducted to learn whether 14 days of treatment with dipyridamole will reduce excessive blood clotting in COVID-19.
Questions: michiganANSWERS@med.umich.edu or 734-647-3949
Principal Investigator: Jason S. Knight, MD, PhD

APS & Lupus Clinical Trials

ANSWERS Study
This observational study is being conducted with the goal of developing better treatments, and ultimately a cure, for APS. Individuals who agree to participate will have the opportunity to donate blood for cutting-edge genetic, transcriptomic, and metabolomic analyses. Participants will also be kept up-to-date on all the newest APS advances and research at University of Michigan.
Questions: michiganANSWERS@med.umich.edu or 734-647-3949
Principal Investigator: Jason S. Knight, MD, PhD
 
Phenotyping Endothelial Cells in APS
This study is being conducted with the goal of developing more precise and individualized treatments for APS. Specifically, we are isolating endothelial (blood vessel) cells from the skin of APS patients to determine why these cells do not function normally. We are especially interested in studying patients with livedo reticularis, a common APS-associated skin rash caused by slow-moving blood flow in vessels near the surface of the skin.
Questions: michiganANSWERS@med.umich.edu or 734-647-3949
Principal Investigator: Jason S. Knight, MD, PhD

APS ACTION International Clinical Database and Repository
This is a multi-center collaborative effort to maintain a secure, web-based clinical database of persistently antiphospholipid antibody-positive individuals so that the natural course of these patients can be followed over the next 10 years.
Questions: michiganANSWERS@med.umich.edu or 734-647-3949
Site Principal Investigator: Jason S. Knight, MD, PhD
 
IMPACT (IMProve Pregnancy in APS with Certolizumab Therapy) Study
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes.
Questions: michiganANSWERS@med.umich.edu or 734-647-3949
Site Principal Investigator: Jason S. Knight, MD, PhD

APS & Lupus Research Studies

Purinergic Modulation of the Autoimmune Vascular Phenotype (NIH-NHLBI)
These studies aim to yield new insight into how a pathway that functions as an endogenous guardian against inflammation may be exploited to counteract the relentless thrombo-inflammatory course of lupus.

Neutrophil Elastase as a Therapeutic Target in Lupus (Lupus Research Alliance)
In this study, we are mapping out the molecular pathways that neutrophil elastase uses to damage the kidneys, heart, and blood vessels in lupus.

Relieving ER Stress in Lupus Neutrophils (Lupus Research Alliance)
The research will test whether a stress-sensing protein in the endoplasmic reticulum spurs neutrophils from patients with lupus to release NETs.

Role of Neutrophil Extracellular Traps in Diabetic Cardiovascular Disease (Department of Defense)
The goal of this project is to dissect the impact of NETs on the diabetic vessel wall, with a particular focus on smooth muscle dysfunction.

Defibrotide as a Regulator of NETs and Endothelial Cells in Antiphospholipid Syndrome (Jazz Pharma)
The major goal of this project is to determine the extent to which defibrotide prevents NET release, especially in response to thrombo-inflammatory stimuli such as antiphospholipid antibodies and activated platelets. 

Clinical Research of Antiphospholipid Syndrome (Burroughs Wellcome Fund)
We are studying APS from every angle in pursuit of a cure.

Role of Neutrophil Extracellular Traps in COVID-19 (NIH-NHLBI)
This project will determine the extent to which NETs are drivers of COVID-19 and therefore potential therapeutic targets.

Modulation of Autoimmunity by Ginger Supplements (NIH-NHLBI)
This project will study the role of natural gingerols in modulating abnormal neutrophil responses in diseases such as antiphospholipid syndrome and lupus.